Officer sold
21K → 18K shares held−13% of their stake
Edwards Lifesciences's CVP, EMEACLA sold $238K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Loading…
Traded Jul 30, 2026 · Filed Jul 30, 2026
Edwards Lifesciences's CVP, JAPAC sold $13K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$12,588
Shares × reported transaction price
7 days after results of Jul 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $86.92 on Jul 30, 2026, 20% above its 52-week low and 9% below its high, after a 2% drop over the previous 30 trading days
52-week range $72.65 (Oct 16, 2025) to $95.18 (Jul 6, 2026), 63% of the way up, from 251 adjusted closes. 30 trading days earlier: $88.58 on Jun 16, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.2% | +3.5% | +0.7% |
| 30 days | +5.4% | +2.7% | +2.8% |
Past results only. Not a forecast.
21K → 18K shares held−13% of their stake
Edwards Lifesciences's CVP, EMEACLA sold $238K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
76K → 75K shares held−2% of their stake
Edwards Lifesciences's CVP, TMTT, Surgical & IHFM sold $106K of Edwards Lifesciences shares. Nobody planned it ahead of time.
